Blue Cross Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Blue Cross Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $2.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Blue Cross Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $2.3M Trade | TransData Nexus

Blue Cross Laboratories Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $2.3M Total Trade · DGFT Verified

Blue Cross Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.3M across 3 products in 3 therapeutic categories. Based on 80 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Gentamicin ($910.1K), Miconazole ($910.1K), Dextromethorphan ($522.2K).

Blue Cross Laboratories Private Limited — Export Portfolio & Destination Treemap

Blue Cross Laboratories Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Blue Cross Laboratories Private Limited? — Company Overview & Market Position

Blue Cross Laboratories Private Limited, established on July 9, 1980, is a prominent Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24230MH1980PTC022825. With an authorized capital of ₹100 crore and a paid-up capital of ₹64.8 crore, Blue Cross Laboratories has demonstrated consistent growth and financial stability.

Over the years, the company has expanded its operations, offering a diverse range of pharmaceutical products across various therapeutic segments. Its commitment to quality and affordability has earned it a significant presence in both domestic and international markets. The company's portfolio includes leading brands such as "MEFTAL" and "TUSQ," which are trusted names in India and abroad.

What Does Blue Cross Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Gentamicin$910.1K 2Miconazole

Product Portfolio — Top 3 by Export Value

Blue Cross Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gentamicin	Antibiotics	$910.1K	30	1.8%	10
2	Miconazole	Antifungals	$910.1K	30	4.6%	5
3	Dextromethorphan	Respiratory & OTC	$522.2K	20	3.5%	6

Blue Cross Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $2.3M. The top category is Antibiotics (38.9% of portfolio), followed by Antifungals (38.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Blue Cross Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Blue Cross Laboratories operates WHO-GMP-certified manufacturing facilities located in Nasik and Goa, India. These facilities are equipped to produce a wide array of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing capabilities are designed to meet both domestic and international standards, ensuring the delivery of high-quality products to its global clientele.

3Key Leadership

The leadership team at Blue Cross Laboratories is headed by Managing Director Bhalchandra Barve Govind, who has been with the company since May 18, 1998. Other key executives include Whole-Time Director Ashish Mangesh Shirsat, appointed on September 1, 2006, and Director Rajendra Yeshwant Padhye, who joined on November 17, 2010. The company's leadership is further strengthened by the presence of directors such as Rohit Jayaramdas Patel and Ketki Raj Wadhawa, appointed on December 5, 2007, and April 15, 2020, respectively.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Blue Cross Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Blue Cross Laboratories has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities in Nasik and Goa are WHO-GMP-certified, enabling them to produce pharmaceutical formulations that meet international regulatory standards. This certification facilitates the company's ability to export products to these markets, ensuring compliance with stringent quality and safety requirements.

2Emerging Markets

The company has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. By obtaining WHO-GMP certification for its manufacturing facilities, Blue Cross Laboratories has enhanced its ability to access these markets, where there is a growing demand for affordable and high-quality pharmaceutical products. The company's expansion into these regions underscores its commitment to improving global healthcare access.

3Geographic Strategy

Blue Cross Laboratories has strategically diversified its geographic footprint to mitigate concentration risks. By expanding into both regulated and emerging markets, the company has balanced its portfolio, reducing dependency on any single region. This approach not only spreads risk but also positions the company to capitalize on growth opportunities in various global markets.

Blue Cross Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, specific details regarding Blue Cross Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's WHO-GMP certification indicates adherence to international manufacturing standards, which is a prerequisite for exporting to regulated markets like the United States. However, for detailed FDA-related information, direct consultation with the FDA's databases or the company's official communications is recommended.

2WHO & EU GMP

Blue Cross Laboratories' manufacturing facilities in Nasik and Goa are certified by the World Health Organization's Good Manufacturing Practices (WHO-GMP). This certification attests to the company's commitment to maintaining high-quality manufacturing standards. While the company has WHO-GMP certification, specific details regarding EU GMP certificates or EDQM status are not publicly disclosed. For comprehensive information, it is advisable to consult the company's official communications or relevant regulatory bodies.

3CDSCO & Indian Regulatory

Blue Cross Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical industry, Blue Cross Laboratories faces competition from both domestic and international companies operating in similar therapeutic segments. While specific market share data is not publicly disclosed, the company's leading brands, "MEFTAL" and "TUSQ," are recognized and trusted names in India and abroad. The company's WHO-GMP-certified manufacturing facilities and diverse product portfolio position it competitively in the market.

2Key Differentiators

Blue Cross Laboratories distinguishes itself through its commitment to quality, affordability, and a diverse product portfolio. The company's WHO-GMP-certified manufacturing facilities in Nasik and Goa enable it to produce a wide range of pharmaceutical formulations that meet international standards. Brands like "MEFTAL" and "TUSQ" exemplify the company's focus on delivering trusted healthcare solutions to a global audience.

3Strategic Position

Blue Cross Laboratories continues to focus on expanding its presence in both regulated and emerging markets. The company's strategic direction emphasizes maintaining high manufacturing standards, as evidenced by its WHO-GMP certification, and offering a diverse range of pharmaceutical products to meet global healthcare needs. Looking ahead, the company is well-positioned to leverage its strengths in quality manufacturing and brand recognition to achieve sustained growth and success.

Buyer Due Diligence Brief — Evaluating Blue Cross Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Blue Cross Laboratories has demonstrated a consistent track record in pharmaceutical manufacturing, with a diverse product portfolio and a commitment to quality. The company's WHO-GMP-certified facilities in Nasik and Goa reflect its dedication to maintaining high manufacturing standards. While specific export volumes and consistency metrics are not publicly disclosed, the company's established presence in both domestic and international markets indicates reliability and trustworthiness as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Blue Cross Laboratories as a supplier:

WHO-GMP Certification: Confirms adherence to international manufacturing standards. Verification can be done through the company's official communications or by contacting the World Health Organization.

CDSCO Manufacturing License: Indicates compliance with Indian national standards for drug manufacturing. Verification can be conducted through the Central Drugs Standard Control Organisation's official channels.

Frequently Asked Questions — Blue Cross Laboratories Private Limited

How many pharmaceutical products does Blue Cross Laboratories Private Limited export from India?

Blue Cross Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Gentamicin ($910.1K), Miconazole ($910.1K), Dextromethorphan ($522.2K). Total export value is $2.3M.

What is Blue Cross Laboratories Private Limited's total pharmaceutical export value?

Blue Cross Laboratories Private Limited's total pharmaceutical export value is $2.3M, based on 80 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Blue Cross Laboratories Private Limited cover?

Blue Cross Laboratories Private Limited exports across 3 therapeutic categories. The largest are Antibiotics (38.9%, 1 products), Antifungals (38.9%, 1 products), Respiratory & OTC (22.3%, 1 products).

Get Full Blue Cross Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.